- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13.03. | Rapport Therapeutics CFO Troy Ignelzi kauft Aktien im Wert von 100.988 US-Dollar | 2 | Investing.com Deutsch | ||
| 13.03. | Rapport Therapeutics-Direktorin Wendy Young erwirbt Aktien im Wert von 61.249 US-Dollar | 4 | Investing.com Deutsch | ||
| 11.03. | Rapport Therapeutics reports Q4 results | 3 | Seeking Alpha | ||
| 11.03. | Rapport Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Rapport Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 11.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 104 | GlobeNewswire (Europe) | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
| 03.03. | Rapport Therapeutics appoints new chief medical officer | 1 | Investing.com | ||
| 03.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.02. | Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% - Should You Sell? | 2 | MarketBeat | ||
| 10.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders | 130 | GlobeNewswire (Europe) | In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical... ► Artikel lesen | |
| 06.12.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures | 381 | GlobeNewswire (Europe) | A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change... ► Artikel lesen | |
| 14.11.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 07.11.24 | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.24 | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.10.24 | This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday | 1 | Benzinga.com | ||
| 14.10.24 | Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3% - What's Next? | 1 | MarketBeat | ||
| 12.06.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement | 221 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 47,480 | -8,64 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
| PORTAGE BIOTECH | 9,630 | +103,59 % | Pre-market Movers: Portage Biotech, XTI Aerospace, Marblegate Acquisition Corp., Cricut, Ecarx Holdings | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.25 A.M. ET).In the Green Portage Biotech Inc (PRTG) is up over 155% at $12.09.
Bowen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,785 | -3,10 % | Recursion Pharmaceuticals CEO verkauft Aktien im Wert von 836.986 US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 47,040 | -1,45 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| QIAGEN | 36,485 | -0,86 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,110 | -0,74 % | How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback | ||
| ARCUTIS BIOTHERAPEUTICS | 15,570 | -4,01 % | Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Sprinting Toward A Profit-Taking Zone | ||
| EVOTEC | 5,810 | -3,17 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,890 | -2,15 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,240 | -2,18 % | Summit Therapeutics Aktie: Wachstum lässt staunen! | Innovativer PD-1/VEGF-Antikörper Ivonescimab wird mit Pfizers ADCs kombiniert, während das Unternehmen trotz finanzieller Herausforderungen Talent akquiriert. Summit Therapeutics hat eine bedeutende... ► Artikel lesen | |
| HUMACYTE | 1,900 | -5,47 % | Aktien New York Ausblick: Wenig verändert erwartet | NEW YORK (dpa-AFX) - Nach drei Erholungstagen dürften die US-Aktienmärkte träge in den Mittwoch starten. Anleger bewerteten die jüngsten Zolldrohungen von Präsident Donald Trump vor dem Hintergrund... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 12,500 | -1,65 % | Raymond James lifts ARS Pharmaceuticals price target to $32 | ||
| ARVINAS | 7,555 | -5,56 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| JANUX THERAPEUTICS | 29,000 | -2,62 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 5,965 | -14,17 % | Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,04 % bei einem Aktienkurs von 10,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.
